Expression Of NCAPG2 And Its Clinical Significance In Breast Cancer

Background: Breast cancer has always been a major problem for clinicians and remains a threat to women’s health.With the development of the economy and people’s living standards,the global incidence of breast cancer is predicted to rise significantly in 2040.With the progress of medicine,the diagnosis and treatment methods for breast cancer are also making continuous progress.There have been many breakthroughs in the treatment of breast cancer,but its high incidence rate and high metastasis rate are still the major concerns of the medical community.Many patients cannot detect breast cancer in the early stage,which will cause treatment delays and affect the patient’s prognosis.Moreover,in the process of breast cancer treatment,its metastasis and recurrence have a huge impact on the prognosis of patients.They also have adverse results on both physical and psychological women.NCAPG2(Non-chromosomal structure maintenance condensin II complex subunit G2)is a member of the Condensin2 n SMC protein family.It is also a regulatory subunit of the condensin II complex and plays a role in chromosome assembly and segregation during mitosis together with the condensin I complex.NCAPG2 is associated with cell cycle progression,DNA replication,and repair.It was first identified as highly expressed in melanoma in 2007.Nowadays,a large number of studies have confirmed that NCAPG2 plays a promoting role in cancer progression,such as lung cancer,liver cancer,cervical cancer,and melanoma.Moreover,abnormal expression of NCAPG2 has also been detected in other diseases,demonstrating that NCAPG2 can also promote the occurrence and development of other diseases.But so far there are few reports on the role of NCAPG2 in breast cancer at home and abroad.And there is no systematic relevant data research and experimental verification.Its related research pathways are still unknown.We preliminarily explored the expression of NCAPG2 in breast cancer and its impact on prognosis through immunohistochemistry and explored whether NCAPG2 can become a new target and marker for breast cancer,thus providing new ideas and methods for the study of breast cancer.Objective: To analyze the expression of NCAPG2 in breast cancer to investigate the relationship between the expression of NCAPG2 and clinicopathologic features and prognosis.Exploring whether NCAPG2 can provide new ideas for the diagnosis and treatment of breast cancer.Methods: Using bioinformatics techniques to analyze the expression of NCAPG2 in related tumors.The breast cancer tissues and corresponding adjacent non-cancerous tissues of 75 patients with confirmed breast cancer in Dalian Central Hospital were collected.The relevant clinicopathological information of these patients was also collected.These patients were followed up by telephone.The analysis of NCAPG2 expression in breast cancer and normal breast tissue,the correlation of NCAPG2 expression with the clinical characteristics of patients by χ 2 test,and the Kaplan-Meier test.To explore the correlation of its expression in breast cancer lesions with DFS and OS in patients.Results: 1.Bioinformatics results: 1.1 The expression of NCAPG2 was significantly different in various tumors,and the expression of NCAPG2 in breast cancer was higher than that in normal breast tissues.(P < 0.01)2.Immunohistochemical correlation test results 2.1 The expression of NCAPG2 in breast cancer was significantly different from that in adjacent non-cancerous tissues.The positive expression rate of NCAPG2 was 70.5% in breast cancer and 30.7% in normal breast tissues.The expression of NCAPG2 was higher in breast cancer.(P < 0.001,χ2 = 27.350)2.2 The expression of NCAPG2 was not correlated with age,ER,PR,HER-2,KI-67 expression and tumor location(p > 0.05);However,the results showed that the expression of NCAPG2 was closely related to tumor diameter(χ2 = 5.220,p = 0.022), lymph node metastasis(χ2 = 4.007,p = 0.045)and histological grade(χ2 = 7.063,p = 0.008)2.3 Kaplan-Meier survival analysis showed that the five-year DFS was 95% in NCAPG2-negative patients and 74.5% in NCAPG2-positive patients.DFS(p = 0.034)was statistically different.Five-year OS was 100% and 94.5% in NCAPG2-negative patients and NCAPG2-positive patients,respectively.OS(p = 0.234)was not statistically significant.Conclusion: NCAPG2 Is statistically different in breast cancer,with higher expression in breast cancer tissue than in normal breast tissue.The expression of NCAPG2 and breast cancer tumor size,lymph node status and histological grade are significantly related.The survival analysis results demonstrated that the expression of NCAPG2 in breast cancer patients was closely correlated with DFS,but the association between the expression of NCAPG2 and OS in patients was not statistically significant.That required more perfect experimental validation.These results suggest that NCAPG2 has great research prospects in breast cancer and may become an important target for breast cancer in the future.